Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Syros Pharmaceuticals excels in heme programs and strategic collaborations

Syros Pharmaceuticals demonstrated strong performance in heme programs, financial resilience, and strategic collaborations, despite challenges in expenses and net losses.
The company's focus on upcoming catalysts and clinical program advancements presents opportunities for growth and innovation in the competitive biopharmaceutical landscape.
Navigating challenges in trial protocols and financial management, Syros Pharmaceuticals aims to leverage strengths in regulatory designations and partnerships for sustainable growth.

Syros Pharmaceuticals reports Q1 progress in key programs and trials

Syros Pharmaceuticals' Q1 2023 performance reflects ongoing investments in late-stage clinical programs amid revenue generation.
The company's focus on key therapeutic areas and proactive approach to trial protocols position it for potential clinical and regulatory milestones.
While facing challenges in financial performance and the need for clarity on trial-related matters, Syros Pharmaceuticals maintains a solid cash position and promising opportunities ahead.

Syros Pharmaceuticals reports Q2 progress in clinical trials and challenges

Syros Pharmaceuticals' Q2 performance reflects a focus on advancing innovative therapies for MDS and AML amid significant R&D investments.
The company faces challenges in managing financials, decision-making timelines, and balancing investments with revenue generation.
Opportunities lie in the potential of tamibarotene, strategic partnerships, and upcoming data readouts to drive future growth and value creation.

Syros Pharmaceuticals advances tamibarotene for hematologic malignancies under new CEO

Syros Pharmaceuticals is strategically advancing tamibarotene for hematologic malignancies under new leadership, with a strong financial performance in the third quarter. While facing challenges in meeting efficacy data expectations, the company has opportunities to address unmet needs in AML and MDS, positioning itself for growth.

Syros Pharmaceuticals reports positive trial results and secures $45M financing

Syros Pharmaceuticals showcased strong performance in clinical trials and financial management in Q4 2023.
While facing challenges in regulatory aspects and profitability, the company is well-positioned for growth.
Opportunities lie in upcoming trial data, product launches, and strategic initiatives for revenue expansion.
Overall, Syros Pharmaceuticals remains optimistic about its future prospects and market positioning.

Syros Pharmaceuticals advances tamibarotene with FDA Fast Track Designation

Syros Pharmaceuticals showcased progress in clinical development programs, particularly with tamibarotene, and secured FDA Fast Track Designation for AML treatment. Despite no revenue in Q1 2024, the company's financial position remains stable with $108.3 million in cash and extended financial flexibility. Challenges include revenue impact from terminated agreements and the need to navigate market competition.

Syros Pharmaceuticals reports Q2 loss, eyes market expansion opportunities

Syros Pharmaceuticals showcased progress on tamibarotene trials with positive results in MDS and AML.
Financial performance in Q2 2024 reflected a net loss but maintained solid cash reserves for operations.
Analyst inquiries and executive insights highlighted strategic focus on pivotal studies and commercialization plans.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will participate in a fireside chat at two upcoming investor conferences. Details are as follows: JMP Securities 2024 Life Sciences Conference Date: Tuesday, May 14 Presentation Time: 11:00 a.m. ET Location: New York Hilton Midtown, 1335 Sixth Avenue, New Y.

Syros to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May 14, 2024 to report its first quarter 2024 financial results and provide a corporate update. To access the live conference call, please dial (800) 549-8228 (domestic) or (289) 819-1520 (internation.

Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Syros Pharmaceuticals (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for

The FDA bestows a Fast Track Designation to Syros' (SYRS) pipeline candidate, tamibarotene, in combination with venetoclax and azacitidine to treat newly diagnosed acute myeloid leukemia. Stock rises.

Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML

Syros Pharmaceuticals (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to tamibarotene in combination with azacitidine and venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) with RARA overexpression as detected by an FDA approved tes.

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of a restricted stock unit (RSU) award for 8,400 shares of Syros common stock to one newly hired employee in connection with commencing employment with Syros. This RSU was granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). T.

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Humana

Disc Medicine Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks You'll Regret Missing This Month - Humana (NYSE:HUM), Disc Medicine (NASDAQ:IRON)

Syros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter and full year ended December 31, 2023 and provided a corporate update. “We are entering 2024 poised for a major transformation,” said Conley Chee, Chief Executive Officer of Syros. “We recently completed enrollment of the 190 patients necessary fo.

Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the enrollment of 190 patients has been completed in the SELECT-MDS-1 Phase 3 clinical trial evaluating tamibarotene in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression. This initial cohort of 190 patients is necessary to su.

Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, March 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update. To access the live conference call, please dial (888) 259-6580 (domestic) or (416) 76.

Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Conley Chee, will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference. Management will also be available for one-on-one meetings. Details are as follows: TD Cowen 44th Annual Health Care Conference Date: Tuesday, M.

Syros to Participate in TD Cowen 44th Annual Health Care Conference

Asure Software

Gritstone Oncology Inc

A company's size does not necessarily dictate the size of it's returns. On the contrary, if their jobs are done correctly, these penny stocks with potential can generate exponential returns that will undoubtedly benefit your investments.

3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential

Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, targeting two different cancer indications.

Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why

Does Syros Pharmaceuticals, Inc. (SYRS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great Choice

Syros Pharmaceuticals, Inc. (SYRS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Syros Pharmaceuticals, Inc. (SYRS) Is a Great Choice for 'Trend' Investors, Here's Why

Syros Pharmaceuticals, Inc. (SYRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stock

The average of price targets set by Wall Street analysts indicates a potential upside of 199.3% in Syros Pharmaceuticals, Inc. (SYRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should Know

Syros Pharmaceuticals (SYRS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Syros Pharmaceuticals (SYRS) Stock Might be a Great Pick

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today highlighted anticipated 2024 milestones to deliver on the value of tamibarotene. “We are beginning the year with tremendous momentum toward our mission of delivering tamibarotene as a new standard of care for the frontline treatment of hematologic malignancies,” said Conley Chee, Chief Exec.

Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene

Astria Therapeutics

Elicio Therapeutics Inc

HighPeak Energy Inc

Unifi

Verrica Pharmaceuticals Inc

As the year wound to a close, biotechs were in focus among the notable insider purchases.

Here's What Insiders Are Buying to Wrap Up the Year

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, announced today that it has priced an underwritten offering of 4,939,591 shares of common stock at an offering price of $4.42 per share, and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 5,242,588 shares of its common stock at an offering price of $4.419 pe.

Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants

Syros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia.

Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced strong and encouraging initial data from its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective, retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia.

Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

News for Syros Pharmaceuticals Stock (SYRS)